Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
Possibly, though this should only happen under provider supervision
Compounded semaglutide is prepared per individual prescription and is not itself FDA-approved as a drug
REDEFINE 2: Efficacy in Type 2 Diabetes REDEFINE 2, announced in March 2025, addressed a distinct population: 1,206 adults with obesity or overweight and type 2 diabetes across 12 countries, randomised in a 3:1 ratio to CagriSema or placebo for 68 weeks
This knowledge informs both protocol design and the interpretation of research outcomes
US$ 26.63
US$ 24.23
US$ 24.68
US$ 23.54
US$ 22.63
US$ 27.47
